CapsoVision, Inc. (CV)
NASDAQ: CV · Real-Time Price · USD
4.580
+0.030 (0.66%)
At close: Sep 26, 2025, 4:00 PM EDT
4.600
+0.020 (0.44%)
After-hours: Sep 26, 2025, 6:44 PM EDT

Company Description

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system.

It offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).

The company also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premise video access and download solution; CapsoAccess, a Capsule data access system; CapsoView, a data access reading device for viewing capsule videos; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services.

It serves gastrointestinal medical practices, clinics, and hospitals. The company sells its products to distributor customers who resell products.

The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May, 2016.

CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

CapsoVision, Inc.
CapsoVision logo
Country United States
Founded 2005
IPO Date Jul 2, 2025
Industry Medical Devices
Sector Healthcare
Employees 90
CEO Kang Wang

Contact Details

Address:
18805 Cox Avenue, Suite 250
Saratoga, California 95070
United States
Phone 408 624 1488
Website capsovision.com

Stock Details

Ticker Symbol CV
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001378325
CUSIP Number 140935107
Employer ID 20-3369494
SIC Code 3845

Key Executives

Name Position
Kang Huai Wang Co-Founder, President, Chief Executive Officer and Director
Douglas Atkinson Head of Global Sales
Kevin Lundquist Executive Officer
Rebecca Petersen Director of Clinical Affairs

Latest SEC Filings

Date Type Title
Sep 26, 2025 8-K Current Report
Sep 3, 2025 8-K Current Report
Aug 14, 2025 10-Q Quarterly Report
Aug 14, 2025 8-K Current Report
Jul 18, 2025 8-K Current Report
Jul 10, 2025 S-8 Securities to be offered to employees in employee benefit plans
Jul 3, 2025 8-K Current Report
Jul 3, 2025 424B4 Prospectus
Jul 2, 2025 CERT Certification by an exchange approving securities for listing
Jul 1, 2025 EFFECT Notice of Effectiveness